Deoxycorticosterone acetate


CAS No. : 56-47-3

(Synonyms: 11-Deoxycorticosterone acetate; DOC acetate; Cortexone acetate)

56-47-3
Price and Availability of CAS No. : 56-47-3
Size Price Stock
100mg $50 In-stock
500mg $100 In-stock
1g $160 In-stock
5g $320 In-stock
10 g Get quote
50 g Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via [email protected]

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. : HY-B1472
M.Wt: 372.50
Formula: C23H32O4
Purity: >98 %
Solubility: DMSO : 16.67 mg/mL (ultrasonic);H2O : < 0.1 mg/mL
Introduction of 56-47-3 :

Deoxycorticosterone acetate (DOCA) is an adrenocortin, acts as a precursor to aldosterone. Deoxycorticosterone acetate is a mineralocorticoid receptor agonist. Deoxycorticosterone acetate can cause severe renal injury, including inflammation, fibrosis, glomerular damage, and proteinuria[1][2]. IC50 & Target:mineralocorticoid receptor[1] In Vivo:Note:
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

Deoxycorticosterone acetate (DOCA) can be used to induce hypertension models[3][4].

Induction of hypertension[3][4]
Background
Deoxycorticosterone acetate (DOCA) inhibits the renin-angiotensin system, resulting in low plasma renin activity, thereby mediating an increase in blood pressure
Specific Modeling Methods
Rat: Sprague-Dawley • Male • ① 250-300 g & ② 160-180 g
Administration: ① 100 mg sustained-release DOCA capsules were implanted subcutaneously and drinking water was replaced with 1% saline; continued for 21 days. ② 15 mg/kg • subcutaneously implanted • drinking water was replaced with 1% saline; twice a week for 2 weeks.
Note
Pretreatment: conduct a right nephrectomy in Sprague-Dawley rats.
Modeling Indicators
Pathological changes: systolic blood pressure increase, superoxide (vascular O2) increase
Opposite Product(s): Atrasentan (HY-15403) A-192621 (HY-120295)

Your information is safe with us.